文献速递肝胆胰外科围术期管理与 ERAS

新辅助化疗联合或不联合放疗在可切除胰腺导管腺癌中的比较

Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma.
PubMed 文献 · JAMA Surg · 2026-01-01

这项回顾性倾向评分匹配队列研究纳入2015至2023年间在两家高容量中心接受新辅助治疗后胰腺切除术的胰腺导管腺癌患者,比较新辅助化疗联合放疗与单纯化疗的肿瘤学结局。匹配后每组226例,放疗与更高的病理完全缓解率、淋巴结阴性率和R0切除率相关,但未改善无事件生存或总生存,局部复发累积发生率无差异。

要点

  • 放疗与更高病理完全缓解率、淋巴结阴性率和R0切除率相关。
  • 放疗未改善无事件生存或总生存。
  • 两组远处复发均为主要首次失败部位,局部复发无差异。

核心结论

  • 在可切除和交界可切除胰腺癌中,新辅助化疗联合放疗与更好的病理缓解相关,但未带来生存获益或减少复发。
  • 结果提示局部控制对以全身进展为驱动力的胰腺癌影响有限。

研究设计与样本

  • 回顾性倾向评分匹配队列研究,纳入2015至2023年两家高容量中心接受新辅助治疗后胰腺切除术的胰腺导管腺癌患者,中位随访44个月。
  • 共1201例连续患者,869例符合标准,最终纳入800例(中位年龄65岁,男性402例[50.2%]),匹配后每组226例。
  • 匹配变量包括年龄、性别、合并症、肿瘤特征、基线CA19-9水平、可切除状态和化疗暴露。

主要发现

  • 匹配后放疗组与单纯化疗组的病理完全缓解率分别为6.6%(15/226)与4.4%(10/226)。
  • 放疗组淋巴结阴性率为61.5%(139/226),单纯化疗组为33.6%(76/226)。
  • 放疗组R0切除率为85.0%(192/226),单纯化疗组为52.2%(118/226)。
  • 两组远处复发均为主要首次失败部位(51.3%[116/226] vs 48.3%[109/226])。

临床怎么用

  • 对于可切除或交界可切除胰腺癌,新辅助化疗后加放疗不应常规期待生存获益。
  • 放疗可考虑用于提高R0切除率和淋巴结阴性率,但需权衡缺乏生存获益。

局限性

  • 回顾性设计可能存在选择偏倚。
  • 仅来自两家高容量中心,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The role of preoperative radiotherapy after neoadjuvant chemotherapy for pancreatic cancer remains controversial. OBJECTIVE: To evaluate whether the addition of radiotherapy to chemotherapy is associated with improved oncologic outcomes in patients undergoing resection for pancreatic cancer. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective propensity score-matched cohort study of patients undergoing pancreatic cancer resection between 2015 and 2023, with a median follow-up of 44 months. Patients were recruited from 2 high-volume referral centers. Of patients undergoing pancreatectomy after neoadjuvant treatment for pancreatic ductal adenocarcinoma, those treated with fluorouracil, leucovorin, irinotecan, and oxaliplatin or gemcitabine/nab-paclitaxel with or without preoperative radiation met eligibility criteria. Patients with metastatic disease, surgery-related mortality, or follow-up less than 12 months were excluded. Treatment groups were matched 1:1 on age, sex, comorbidity, tumor characteristics, baseline carbohydrate antigen 19-9 level, resectability status, and chemotherapy exposure. EXPOSURE: Neoadjuvant chemotherapy with or without radiotherapy. MAIN OUTCOMES AND MEASURES: Event-free survival, pattern of recurrence, and overall survival. RESULTS: Of 1201 consecutive patients undergoing pancreatectomy after neoadjuvant treatment for pancreatic ductal adenocarcinoma, 869 met eligibility criteria. Among 800 included patients (median [IQR] age, 65 [58-71] years; 402 men [50.2%]), 438 received neoadjuvant chemotherapy and radiotherapy and 362 chemotherapy alone. After matching, 226 patients per group were analyzed; most had resectable (117 of 226 [51.1%]) or borderline-resectable (104 of 226 [46.5%]) disease. Radiotherapy was associated with higher rates of pathologic complete response (15 of 226 [6.6%] vs 10 of 226 [4.4%]), node-negative disease (139 of 226 [61.5%] vs 76 of 226 [33.6%]), and R0 resection (192 of 226 [85.0%] vs 118 of 226 [52.2%]). Recurrence patterns were similar, with distant recurrence as the predominant first site of failure in both groups (116 of 226 [51.3%] vs 109 of 226 [48.3%]). In competing risk analysis, the cumulative incidence of locoregional recurrence did not differ (subdistribution hazard ratio [HR], 0.90; 95% CI, 0.53-1.54; P = .71). Radiotherapy was not associated with improved event-free survival (HR, 1.10; 95% CI, 0.88-1.37; P = .38) or overall survival (HR, 1.02; 95% CI, 0.79-1.32; P = .84). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that although the addition of radiotherapy to neoadjuvant chemotherapy was associated with an improved pathologic response, it was not associated with survival benefit or reduced recurrence in resectable and borderline-resectable pancreatic cancer. These findings highlight the limited impact of locoregional control in a disease driven by systemic progression.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. De Stefano F, Wu NF, Belfiori G, et al. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2026. PMID: 42647021. doi:10.1001/jamasurg.2026.3716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。